ReviewFrontiers in medicine2022
Current Trends in Circulating Biomarkers for Melanoma Detection.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Review
- Circulating Cytokines in Melanoma Prognosis: Current Evidence and Future Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Microneedles meet photomedicine: emerging strategies for diagnosis and therapy of skin diseases.Nanoscale advances · 2026Review
- Hydrogel-based delivery systems for cutaneous melanoma therapy: from chemical design and crosslinking strategies to structure-activity relationships.RSC advances · 2026Review
- Circulating Tumor DNA in Melanoma: Advances in Detection, Clinical Applications, and Integration with Emerging Technologies.International journal of molecular sciences · 2026Review
- Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma.JCO precision oncology · 2026Article
- Ferroptosis, pyroptosis, and necroptosis in melanoma: regulatory cell death pathways and their implications for immunotherapy.Frontiers in oncology · 2026Review
- Circulating tumor cells as biomarkers in melanoma: techniques, challenges, and clinical applications.Frontiers in cell and developmental biology · 2026Review
- Liquid Biopsy for Cutaneous Melanoma: Opportunities and Challenges in Detecting and Characterizing Circulating Tumor Cells.Journal of dermato-oncology · 2025Article
- Artemisinin Suppressed Melanoma Recurrence and Metastasis after Radical Surgery through the KIT/PI3K/AKT Pathway.International journal of biological sciences · 2025Article
- Applying Neural Networks to Analyse Inflammatory, Sociodemographic, and Psychological Factors in Non-Melanoma Skin Cancer and Colon Cancer: A Statistical and Artificial Intelligence Approach.Diagnostics (Basel, Switzerland) · 2024Article
- Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions.Cancers · 2024Review
- Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma.Biomedicines · 2024Review
- Immunotherapy in melanoma: advances, pitfalls, and future perspectives.Frontiers in molecular biosciences · 2024Review
- Review
- Article
- Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach.International journal of molecular sciences · 2023Review
- An update on methods for detection of prognostic and predictive biomarkers in melanoma.Frontiers in cell and developmental biology · 2023Review
- Cellular miR-6741-5p as a Prognostic Biomarker Predicting Length of Hospital Stay among COVID-19 Patients.Viruses · 2022Article
- Extracellular vesicles and melanoma: New perspectives on tumor microenvironment and metastasis.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanomas have increased in global incidence and are the leading cause of skin cancer deaths. Whilst the majority of early-stage, non-metastatic melanomas can be cured with surgical excision alone, ~5% of patients with early melanomas will experience recurrence following a variable disease-free interval and progression to metastatic melanoma and ultimately death. This is likely because of primary tumor heterogeneity and progressive clonal divergency resulting in the growth of more aggressive tumor populations. Liquid biomarkers have the advantage of real-time, non-invasive longitudinal monitoring of tumor burden and heterogeneity over tissue markers. Currently, the only serological marker used in the staging and monitoring of melanoma is serum lactate dehydrogenase, which is not sufficiently specific or sensitive, and is not used routinely in all centers. An ideal melanoma biomarker would be used to identify patients who are at high-risk of primary melanoma, screen for relapse, detect early-stage melanoma, provide treatment outcomes to personalize systemic treatment, follow tumor heterogeneity, provide prognostic data before, during and after treatment, and monitor response to treatment. This review provides a summary of the current research in this field with a specific focus on circulating tumor cells, circulating tumor DNA, microRNA, and extracellular vesicles which may serve to suit these goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.